INTRODUCTION
Anemia is a complication of chronic kidney disease (CKD), and is twice as common in patients with any stage of CKD as in the general population [1] .
Anemia of CKD increases in prevalence and severity as kidney function declines [2] , with over 90% of patients who progress to renal replacement therapy becoming anemic [3] .
Anemia of CKD results primarily from decreased production of endogenous erythropoietin (EPO) by the kidneys [4] . There is a clear clinical rationale for correcting low hemoglobin (Hb) levels in patients with CKD, as persistent anemia is associated with increased risk of cardiac complications and mortality and impaired quality of life [5] [6] [7] . The introduction of exogenous erythropoiesis-stimulating agents (ESAs) to clinical practice transformed the care of patients with CKD by ameliorating anemia, reducing transfusion requirements and improving quality of life [8] .
The first-generation recombinant ESAs (epoetin alfa and beta) were short-acting, generally requiring administration three times per week [9] . While short-acting originator (and, more recently, their biosimilar) ESAs remain available, using the subsequently developed longer-acting ESAs, which require less frequent dosing, appears to reduce the burden of administration on patients, caregivers and healthcare professionals [10] .
The two longer-acting ESAs, darbepoetin alfa (DA) and methoxy polyethylene glycol-epoetin beta (PEG-Epo), combine a significantly increased half-life with a lower binding affinity for the EPO receptor, allowing them to stimulate erythropoiesis for longer periods and to be administered less frequently [9, 11] . DA, launched in 2001, has five N-linked oligosaccharide chains rather than the three contained in short-acting epoetins, conferring an approximately threefold longer serum halflife and mean residence time, and is approved for administration to hemodialysis patients once a week (QW) or once every 2 weeks (Q2W) [9, 11, 12] . Compared with epoetin beta, PEG-Epo, launched in 2009, has an increased serum half-life that is due to the addition of methoxy polyethylene glycol (PEG), and is approved for administration to patients on dialysis Q2W or once a month (QM) [9, 11, 13] .
When switching patients from short-acting
ESAs to DA or PEG-Epo, clinicians have reference to the dose conversion schedules recommended in the DA and PEG-Epo labels [12, 13] . The PEG-Epo label also provides recommended dose ranges when converting patients from DA to PEG-Epo [13] , and Hb and dose data for patients switching from DA to PEG-Epo are available from randomized clinical studies [14, 15] and from observational studies in routine clinical practice [16] . In contrast, there is no label guidance on switching patients from PEG-Epo to DA, and to our knowledge only a single study, published only in abstract form, has examined outcomes associated with switching from PEG-Epo to DA [17] The primary outcome measure of the TRANSFORM study was Hb concentration at monthly intervals. Secondary outcome measures included PEG-Epo and DA doses over time, the dose ratio of DA to PEG-Epo at switching, and the incidence of Hb excursions below 10 g/dL and above 12 g/dL. These Hbconcentration thresholds were selected for examination of Hb excursions because 10-12 g/dL is the target Hb range according to the guidance in the product labels for both PEGEpo and DA [12, 13] , and this target range is 
Statistical Methods
As no formal hypothesis was tested in this study, all analyses were descriptive; no tests of statistical significance were performed. Average
Hb values were reported using arithmetic means, and mean weekly ESA doses were reported using geometric means due to the skewed nature of the dosing data. Two-sided 95% confidence intervals (CIs) were calculated for mean Hb and weekly ESA doses.
The dose ratio at switching for each subject was calculated by subtracting the logtransformed weekly dose of PEG-Epo at switch from the log-transformed weekly first dose of DA. The geometric mean dose ratio was derived from the exponential of the arithmetic mean of the log-transformed dose ratio.
Analyses were conducted for all eligible enrolled subjects who received at least one 
RESULTS
A total of 1,027 eligible patients were enrolled at 42 hemodialysis centers in seven European countries; more than half (56%) in France (Table 1) The primary outcome measure, Hb concentration, was generally stable in the post-switch period, rising by less than 0.3 g/dL in the overall cohort from month -1 (i.e., the As shown in Fig. 2 , the subgroup analysis stratified by ESA dose ratio at switch revealed that the change in mean monthly Hb concentration in the post-switch period was driven by patients' dose ratio at switching.
Whereas the elevation in mean monthly Hb concentration at month 3 post-switch was greatest in patients with a dose ratio of [1.2, this trend was reversed in patients with a dose ratio at switch of \0.8, with mean monthly Hb declining from the time of switching to month 4 before rising again to month 6 post-switch. with a dose ratio of 0.8-1.2 was roughly parallel to that of the overall cohort. Notably, despite these differences in mean monthly Hb between dose-ratio subgroups, Hb concentration converged by the end of the post-switch period; by month 6, mean Hb concentration was within the range of 11.1-11.5 g/dL across all three dose-ratio subgroups.
Mean monthly Hb concentration for patients
Trends in post-switch DA dosing were roughly the opposite of the trends seen for Hb concentration. In the overall cohort, the geometric mean weekly dose of DA was highest at 1 month post-switch and fell to below pre-conversion dosing levels by month 3 (Fig. 3) . The geometric mean (95% CI) PEGEpo dose at month -1 was 27.4 (26.0, 28.8) lg/ week, with ESA dose rising to a peak at month 1 with a DA dose of 29.4 (27.9, 30.9) lg/week, then declining to 23.3 (21.9, 24.9) lg/week at month 4 and reaching 25.6 (24.1, 27.1) lg/week at month 6.
In the subgroup analysis stratified by dose ratio at switching, the reduction in geometric mean weekly dose observed from month 1 to month 3 was greatest in patients with a dose ratio of [1.2 (Fig. 3) . The trend in geometric mean weekly DA dose for patients with a dose ratio of 0.8-1.2 was similar to that of the overall cohort. In contrast, geometric mean weekly DA doses for patients with a dose ratio \0.8 did not show the same U-shaped trend as for the other dose-ratio categories, but instead increased over the postswitch period. By month 6, geometric mean DA dose was within the range of 23.9-27.0 lg/week across all three dose-ratio subgroups. Overall, the geometric mean (95% CI) dose ratio at switching was 1.06 (1.01, 1.11), and more than three-quarters of patients (77.8%) had a dose ratio of C0.8 (Table 3) . By month 6, the geometric mean (95% CI) dose ratio had decreased to 0.88 (0.83, 0.93), and the proportion of patients with a dose ratio of C0.8 had dropped to 63.0%. As shown in Fig. 4 , there was considerable variability in dose ratio at switch across countries, with geometric mean (95% CI) dose ratio at switch ranging from 0.72 (0.57, 0.90) in the Netherlands to 1.36 (1.17, 1.59) in Spain. Endpoints were summarized using geometric means CI confidence interval, DA darbepoetin alfa, PEG-Epo methoxy polyethylene glycol-epoetin beta a Mean weekly doses were calculated per patient by calculating a mean daily dose for the interval (by dividing each dose evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose; implausible weekly doses [150 lg were excluded b Mean weekly dose for the first DA dose divided by the mean weekly dose of PEG-Epo at switch compared to the pre-switch period, but by month 6 had dropped to a similar incidence as had been observed pre-switch (Table 4) .
Use of IV iron supplementation increased steadily from 67% of subjects at month -3 to 81% by month 3, and then declined to 71% by month 6. The most common iron preparation was saccharated iron oxide, administered to over 80% of subjects receiving IV iron supplementation. Mean weekly iron dose ranged from 255 mg at month -3 to 218 mg CI confidence interval, DA darbepoetin alfa, Hb hemoglobin, PEG-Epo methoxy polyethylene glycol-epoetin beta at month -1, and was 261 mg at month 6.
Mean TSAT was 28.9% in the 3 months preswitch, 26.9% over months 1-3, and 27.6% over months 4-6. Mean serum ferritin was 487.9 lg/L in the 3 months pre-switch, 459.3 lg/L over months 1-3, and 509.6 lg/L over months 4-6.
DISCUSSION
The primary finding of this observational cohort analysis of hemodialysis patients TRANSFORM also indicated that higher DA doses were not required in these patients switching from PEG-Epo. There was considerable variation in the dose ratio of DA to PEG-Epo at the time of switching, which may have been driven by the lack of label guidance on dose conversion from PEG-Epo to DA, in the absence of which dose conversion likely reflected clinicians' preferences. However, there was no difference in mean weekly ESA dose at the end of the post-conversion period compared with pre-conversion dose, regardless of patients' dose ratio at switch.
ACKNOWLEDGMENTS
Sponsorship and article processing charges for this study were funded by Amgen (Europe) GmbH, Zug, Switzerland. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis Publication management support was provided by Jennifer Corrigan, Medical Writing etc., Oxford, UK. Editorial assistance in the preparation of this manuscript was provided by W. Mark Roberts, Montreal, Canada. Support for publication management and editorial assistance was funded by Amgen (Europe)
GmbH. Jan Donck is the guarantor for this article, and takes responsibility for the integrity of the work as a whole. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. Conflict of interest. Jan Donck has received honoraria from Amgen Inc., Thousand Oaks, CA, USA and Roche Europe, Basel, Switzerland.
Contributors

Lourdes
Gonzalez-Tabares and Jacques
Chanliau declare no conflict of interest. Heike
Martin has received honoraria from Amgen
